Latest news with #MASI
Morocco World
3 days ago
- Business
- Morocco World
Casablanca Stock Exchange Hits MAD 1 Trillion Mark for First Time in History
Marrakech – The Casablanca Stock Exchange closed on a high note Friday, with its benchmark MASI index surpassing the symbolic threshold of 19,000 points and reaching a record MAD 1 trillion (US$100 billion) market capitalization for the first time in its history. The MASI index gained 1.30% to close at 19,168.83 points, bringing its year-to-date performance to an impressive 29.75%. The MASI 20, which tracks the 20 most liquid companies, rose 1.28% to 1,578.22 points, while the MASI ESG advanced 1.26% to 1,318.74 points. Trading was robust, with transactions reaching MAD 466 million (US$46.6 million) on the central market. Attijariwafa Bank led activity, accounting for MAD 62 million (US$6.2 million) in trades and posting a significant 3.57% gain to close at MAD 725 (US$72.5). Maroc Telecom followed closely with equivalent trading volume and a 2.54% increase to MAD 121 (US$12.1). Among emerging stocks, Vicenne, a medical equipment company, continued to capture investor attention. Introduced on the exchange just one week ago, the stock is now trading at MAD 345 (US$34.5), representing a remarkable 46% surge since its initial public offering. Vicenne's IPO raised MAD 500 million (US$50 million) and was oversubscribed 64 times, generating demand worth MAD 32 billion (US$3.2 billion). Other notable performers included Maghreb Oxygène, which jumped 9.96% to MAD 425 (US$42.5), and Sothema, gaining 9.56% to close at MAD 1,810 (US$181). On the downside, Sanlam Maroc recorded the day's steepest decline at 6.75%, falling to MAD 1,865 (US$186.5). This market rally comes amid favorable economic conditions despite global uncertainties. According to the High Commission for Planning (HCP), Morocco's economic growth accelerated to 4.8% in the first quarter of 2025, up from 3% a year earlier. This performance was primarily driven by a 4.6% increase in non-agricultural activities, stimulated by major infrastructure projects related to the 2025 African Cup of Nations and the 2030 World Cup. Sectoral indicators confirm this positive trend. Cement sales, a key barometer for construction activity, grew by 9.8% to reach 6.8 million tons by the end of June, despite the slowdown during Eid Al-Adha. The automotive sector posted impressive growth, with sales up 36.6% in the first half of the year, totaling 88,728 units. Agriculture also contributed to the recovery with a 4.5% increase in added value during the first quarter. This strategic sector still represents between 11% and 15% of GDP and accounts for nearly 40% of national employment. On the external front, the trade deficit widened to MAD 133 billion (US$13.3 billion) by the end of May, primarily due to increased imports of capital goods and construction materials. However, this deficit is partially offset by a growing surplus in services, fueled by tourism recovery and strong business services. The current account deficit remains contained at around 2% of GDP. Inflation continues to decline, averaging 2% in the first quarter before dropping to 0.7% in April and 0.4% in May, mainly due to falling food prices. In this context, Bank Al-Maghrib has maintained its key interest rate at 2.25%, awaiting greater visibility on geopolitical tensions and the international environment. Public finances remain under control, with the central bank projecting a budget deficit of 3.9% of GDP for 2025, despite sustained public investment. This trajectory is supported by increased tax revenues and rigorous expenditure management. Read also: Morocco to Help Mauritania Create Nouakchott Stock Exchange Tags: Casablanca stock exchange
Time of India
30-05-2025
- General
- Time of India
‘All excavation reports need proper vetting and editing before publication'
Chennai: A week after a controversy broke out over its seeking corrections to the draft report on the Keeladi excavations, especially the dating of the settlement's first period to between the 8th century BCE and the 5th century BCE, the Archaeological Survey of India (ASI) on Thursday said, "All reports need proper vetting, editing, proofreading, and designing before they are sent for publication. " "That the ASI is uninterested in the publication of the Keeladi report is a figment of imagination, which aims purposefully to paint the department in bad colours," it further said in a statement. Archaeologist K Amarnath Ramakrishna, who excavated the Keeladi site that proved the existence of an urban centre during the Sangam Age, classified the site's age into three different periods: the pre-early historic period (from the 8th century BCE to the 5th century BCE), the mature early historic period (from the 5th century BCE to the end of the 1st century BCE), and the post-early historic period (from the end of the 1st century BCE to the 3rd century CE). More than two years after the submission of the 982-page report, ASI's director (exploration & excavation), Hemasagar A Naik, asked Ramakrishna to make "corrections" in his draft report on the Keeladi excavations "to make it more authentic" as per the suggestions of two experts who were not named. Naik said Keeladi could at best be dated to around 300 BCE. Ramakrishna defended his findings, saying the final report has "all documentary evidence and chronological sequence". Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Giao dịch CFD với công nghệ và tốc độ tốt hơn IC Markets Đăng ký Undo In response to the adverse reactions to its demand, ASI said: "In a set process, after the submission of the reports by the excavators, those are then sent to various subject experts, who are requested to vet the reports for publication. Various alterations, as suggested by the subject experts, are carried out by the excavators and resubmitted finally for publication. These are then published as Memoirs of the Archaeological Survey of India (MASI). " "The same procedure was adopted in the case of the Keeladi report, wherein the report was sent for vetting to experts. Accordingly, the excavator of the Keeladi has been communicated the suggestions of the experts for making necessary corrections in the draft report submitted by him, but he did not carry out the correction to date," it said. "The story being circulated in a part of the media is misleading, untrue, and is absolutely and vehemently denied. The Director General and the ASI officials understand the importance of an excavated site, but all reports need proper vetting, editing, proofreading, and designing before they are sent for publication," the release said. It also called the notion that the ASI is uninterested in the publication of the Keeladi report "a figment of imagination which aims purposefully to paint the department in bad colours". "The letter from the director (Excavations & Explorations) is a routine matter which the Director (EE) regularly writes to the excavators for carrying out changes in the report or otherwise," the release said. Madurai MP Su Venkatesan, who raised the issue on various platforms, called the release a joke.
The Hindu
29-05-2025
- General
- The Hindu
ASI dismisses claim of disinterest in publishing Keeladi report as ‘figment of imagination'
The Archaeological Survey of India (ASI) on Thursday (May 29, 2025) dismissed as a 'figment of imagination' the allegation that it is disinterested in publishing the report on the Keeladi excavation. It called such claims misleading and an attempt to malign the department. Recently, the ASI had asked archaeologist Amarnath Ramakrishna, who unearthed an ancient civilisation in Keeladi in Sivaganga district, to resubmit his report about the excavation after making necessary corrections for taking further action. However, Mr. Ramakrishna defended his conclusions and refused to revise the findings. In a statement released through the Press Information Bureau, the ASI said it regularly publishes reports on excavated sites and places great emphasis on this aspect, since much time, energy, and money are invested in every excavation. Without publication, the basic purpose of the excavation remains unfulfilled. After the submission of reports by excavators, they are sent to subject experts for vetting. Various alterations, as suggested by the subject experts, are carried out by the excavators and resubmitted finally for publication. The reports are eventually published as Memoirs of the Archaeological Survey of India (MASI). 'The same procedure was adopted in case of the Keeladi report, wherein the report was sent for vetting to experts. Accordingly, the excavator of Keeladi was communicated the suggestions of the experts for making necessary corrections in the draft report submitted by him, but he did not carry out the corrections till date,' the ASI said. 'The story being circulated in a part of the media is misleading and untrue. The Director General and the ASI officials understand the importance of an excavated site, but all reports need proper vetting, editing, proofreading, and designing before being sent for publication. That the ASI is uninterested in publication of the Keeladi report is a figment of imagination, which aims purposefully to paint the department in bad colours,' it added.
Yahoo
20-05-2025
- Business
- Yahoo
MASI Q1 Earnings Call: Revenue Tops Expectations, Focus Shifts to Healthcare Core Amid Tariff Headwinds
Medical tech company Masimo (NASDAQ:MASI) reported Q1 CY2025 results topping the market's revenue expectations , with sales up 9.5% year on year to $372 million. The company expects the full year's revenue to be around $1.52 billion, close to analysts' estimates. Its non-GAAP profit of $1.36 per share was 12.6% above analysts' consensus estimates. Is now the time to buy MASI? Find out in our full research report (it's free). Revenue: $372 million vs analyst estimates of $367.9 million (9.5% year-on-year growth, 1.1% beat) Adjusted EPS: $1.36 vs analyst estimates of $1.21 (12.6% beat) Adjusted EBITDA: $123.8 million vs analyst estimates of $108.5 million (33.3% margin, 14.1% beat) Management lowered its full-year Adjusted EPS guidance to $4.98 at the midpoint, a 5.2% decrease Operating Margin: 21%, up from 15.6% in the same quarter last year Free Cash Flow Margin: 7.7%, down from 11.1% in the same quarter last year Constant Currency Revenue rose 10.5% year on year (-12.5% in the same quarter last year) Market Capitalization: $8.44 billion Masimo's first quarter results were driven by double-digit growth in core healthcare sales, margin expansion, and operational efficiencies. CEO Katie Szyman attributed performance to strong demand for patient monitoring products, a successful large contract renewal, and improved cost controls. She also cited early progress in her commercial strategy and highlighted the company's commitment to innovation as foundational for future growth. Looking ahead, management's guidance reflects the impact of new tariffs and continued investments in commercial and R&D initiatives. CFO Micah Young described the tariff environment as fluid, noting that mitigation plans are in progress but difficult to quantify for the full year. The company's outlook is further shaped by the sale of its consumer audio business, with proceeds expected to support share repurchases. Szyman acknowledged ongoing uncertainty from tariffs and emphasized Masimo's focus on operational execution and margin discipline. Masimo's management identified several drivers behind Q1 performance and upcoming changes to its business focus. The sale of the consumer audio division and a renewed emphasis on healthcare technology are central to its evolving strategy. Divestiture of Sound United: Masimo entered an agreement to sell its consumer audio business, Sound United, allowing the company to concentrate resources on its healthcare segment. Management stated that the sale will help sharpen the company's focus on patient monitoring and hospital solutions. Operational margin gains: Operating margin improvement was attributed to last year's cost optimization measures and a shift towards higher-value healthcare products. CFO Micah Young noted that these actions resulted in a 750 basis point annual increase. Sales force restructuring: CEO Katie Szyman outlined a transition from product-based to regionally-focused sales teams. This shift is intended to leverage the full product portfolio and increase market penetration for advanced monitoring categories such as capnography and hemodynamics. Product innovation pipeline: Szyman highlighted next-generation patient monitors with AI-based algorithms as a key area of investment. These upcoming launches aim to expand Masimo's presence in acute and post-acute care settings. Tariff mitigation planning: Management discussed detailed scenario planning to address new U.S. and China tariffs. Young explained that supply chain adjustments and sourcing changes are under evaluation, with mitigation steps expected to be phased in as regulatory clarity improves. Masimo's forward-looking performance will depend on its ability to offset tariff pressures, execute its healthcare strategy, and maintain commercial momentum while investing in innovation. Tariff cost management: Management is actively scenario-planning to mitigate the impact of recently imposed tariffs, including supply chain shifts and potential pricing adjustments, with the goal of reducing margin pressure through 2025. Healthcare business refocus: The sale of the consumer audio division will free up resources to accelerate investments in patient monitoring technologies, AI-driven products, and sales force expansion—all positioned as growth catalysts for the core business. Operational investments and risks: Increased spending on commercial excellence and R&D, coupled with macroeconomic uncertainties such as labor costs and regulatory shifts, may create short-term margin volatility even as management expects long-term leverage. Frederick Wise (Stifel): Asked about the revenue and margin impact of a large contract and how underlying growth trends will normalize next quarter. Management explained the timing effect and stated that underlying demand remains strong, with seasonality expected to drive Q2 results. Vik Chopra (Wells Fargo): Queried whether tariffs will affect long-term margin goals and sought clarification on use of proceeds from the Sound United sale. CFO Micah Young confirmed ongoing margin expansion is expected and that share repurchases are prioritized over debt repayment. Jason Bednar (Piper Sandler): Requested insight into OEM partner signals on hospital spending and the rationale for confidence in guidance despite a recent cybersecurity incident. Management cited recurring revenue strength and robust protocols for addressing the incident. Mike Matson (Needham): Probed the strategy for hemodynamic monitoring and whether share repurchases will take precedence over debt repayment. CEO Szyman described the plan to integrate hemodynamics into next-gen monitors and focus on mid-to-low acuity hospital segments. Matt Taylor (Jefferies): Sought details on the margin expansion potential and the cadence of tariff impacts throughout the year. Management highlighted ongoing investments and explained that tariff effects will be weighted toward the fourth quarter. In the coming quarters, the StockStory team will monitor (1) the progress of Masimo's sales force restructuring and its effect on new product adoption, (2) execution of supply chain and sourcing adjustments in response to tariffs, and (3) the pace and success of innovation in AI-based patient monitoring. Updates on the Sound United sale closing and deployment of proceeds will also be key markers for fundamental performance. Masimo currently trades at a forward P/E ratio of 28.7×. Should you load up, cash out, or stay put? Find out in our free research report. Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years. Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
07-05-2025
- Business
- Yahoo
Masimo's (NASDAQ:MASI) Q1: Beats On Revenue But Stock Drops
We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. Masimo's recent performance marks a sharp pivot from its five-year trend as its revenue has shown annualized declines of 7.3% over the last two years. Reviewing a company's long-term sales performance reveals insights into its quality. Any business can have short-term success, but a top-tier one grows for years. Luckily, Masimo's sales grew at a solid 15.1% compounded annual growth rate over the last five years. Its growth beat the average healthcare company and shows its offerings resonate with customers. Founded in 1989 to solve the "unsolvable problem" of accurate pulse oximetry during patient movement, Masimo (NASDAQ:MASI) develops and manufactures noninvasive patient monitoring technologies, including its breakthrough pulse oximetry systems that accurately measure blood oxygen levels even during patient movement. Katie Szyman, Chief Executive Officer of Masimo, said, 'Since joining Masimo as CEO three months ago, I have been focused on immersing myself in our business. I have visited customers, employees, manufacturing and R&D sites, evaluated our innovation pipeline, and attended national meetings with our sales team. My key takeaways are that our technology advantage is real, we have a stellar team that is enthusiastic about the path forward at Masimo, and we have an opportunity to build and improve from a position of meaningful strength. Our first quarter results clearly demonstrate the earnings power of our core business as we delivered double-digit revenue growth and exceptional earnings growth.' Is now the time to buy Masimo? Find out in our full research report . Medical tech company Masimo (NASDAQ:MASI) reported Q1 CY2025 results exceeding the market's revenue expectations , but sales fell by 24.5% year on year to $372 million. The company expects the full year's revenue to be around $1.52 billion, close to analysts' estimates. Its non-GAAP profit of $1.36 per share was 12.5% above analysts' consensus estimates. Story Continues Masimo Year-On-Year Revenue Growth We can dig further into the company's sales dynamics by analyzing its constant currency revenue, which excludes currency movements that are outside their control and not indicative of demand. Over the last two years, its constant currency sales averaged 5% year-on-year declines. Because this number is better than its normal revenue growth, we can see that foreign exchange rates have been a headwind for Masimo. Masimo Constant Currency Revenue Growth This quarter, Masimo's revenue fell by 24.5% year on year to $372 million but beat Wall Street's estimates by 1.1%. Looking ahead, sell-side analysts expect revenue to decline by 21.8% over the next 12 months, a deceleration versus the last two years. This projection is underwhelming and indicates its products and services will face some demand challenges. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. Operating Margin Operating margin is an important measure of profitability as it shows the portion of revenue left after accounting for all core expenses – everything from the cost of goods sold to advertising and wages. It's also useful for comparing profitability across companies with different levels of debt and tax rates because it excludes interest and taxes. Masimo was profitable over the last five years but held back by its large cost base. Its average operating margin of 7.2% was weak for a healthcare business. Analyzing the trend in its profitability, Masimo's operating margin decreased by 32.8 percentage points over the last five years. The company's two-year trajectory also shows it failed to get its profitability back to the peak as its margin fell by 19.5 percentage points. This performance was poor no matter how you look at it - it shows its expenses were rising and it couldn't pass those costs onto its customers. Masimo Trailing 12-Month Operating Margin (GAAP) This quarter, Masimo generated an operating profit margin of 21%, up 14.1 percentage points year on year. This increase was a welcome development, especially since its revenue fell, showing it was more efficient because it scaled down its expenses. Earnings Per Share We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company's growth is profitable. Masimo's EPS grew at a solid 8% compounded annual growth rate over the last five years. However, this performance was lower than its 15.1% annualized revenue growth, telling us the company became less profitable on a per-share basis as it expanded due to non-fundamental factors such as interest expenses and taxes. Masimo Trailing 12-Month EPS (Non-GAAP) Diving into Masimo's quality of earnings can give us a better understanding of its performance. As we mentioned earlier, Masimo's operating margin improved this quarter but declined by 32.8 percentage points over the last five years. This was the most relevant factor (aside from the revenue impact) behind its lower earnings; taxes and interest expenses can also affect EPS but don't tell us as much about a company's fundamentals. In Q1, Masimo reported EPS at $1.36, up from $0.77 in the same quarter last year. This print easily cleared analysts' estimates, and shareholders should be content with the results. Over the next 12 months, Wall Street expects Masimo's full-year EPS of $4.99 to grow 8.5%. Key Takeaways from Masimo's Q1 Results We were impressed by how significantly Masimo blew past analysts' constant currency revenue and EPS expectations this quarter. On the other hand, its EBITDA missed and it lowered its full-year EPS guidance. Zooming out, we think this was a mixed quarter. The market seemed to be hoping for more, and the stock traded down 5.9% to $151.25 immediately after reporting. So should you invest in Masimo right now? The latest quarter does matter, but not nearly as much as longer-term fundamentals and valuation, when deciding if the stock is a buy. We cover that in our actionable full research report which you can read here, it's free.
